NCT06575257View on ClinicalTrials.gov

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2029

Conditions
Prostate Cancer
Interventions
DRUG

Darolutamide

600 mg orally twice daily for 12 weeks before radical prostatectomy

DRUG

Goserelin 3.6 mg

3.6 mg goserelin hypodermic once per 4 weeks

Trial Locations (1)

710032

RECRUITING

The First Affillated Hospital, the Air Force Medical University, Xi’an

All Listed Sponsors
lead

Xijing Hospital

OTHER